Provides debt financing to life sciences companies. Secures investments with royalties and cash flows from approved products. Now — the numbers.
This is an established company with proven profits.
Average growth of 12% a year over the last 4 years. Every year shown ended in profit.
The market pays 8× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
The stock trades below its recent peak — about 9% off the top. A pullback, not a collapse.
The net profit margin is 93% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 12% a year on average.
It pays out $0.13 per share each year — regular cash for whoever holds the stock.
The stock sits at $0.93. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
The price action doesn’t yet back an upward turn.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.